NCT06458712 - Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2028

Conditions

Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases)

Interventions

DRUG

DSB2455

PARP1 inhibitor

Trial Locations (7)

RECRUITING

START La Rioja, Hospital Universitario San Pedro, Logroño

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

RECRUITING

Hospital Universitari Vall d'Hebron, Barcelona

RECRUITING

START Barcelona, CIOCC, Hospital Universitario Nou Delfos, Barcelona

RECRUITING

Hospital Universitario Reina Sofía, Córdoba

RECRUITING

Hospital 12 de Octubre, Madrid

RECRUITING

START Madrid-CIOCC, Hospital Universitario HM Sanchinarro, Madrid